Sotrovimab vs placebo
Clinical progression: oxygen requirement (≥ 5 WHO scale) · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)
Sotrovimab may leads to lower clinical progression: oxygen requirement (≥ 5 WHO scale) compared with placebo (low certainty).
1 finding from 1 review
- SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes onlyRR 0.11 [0.02, 0.45]1 study · 583 participantsLow